



# Lipid Lowering Therapy to Modify Plaque Microstructures: Insights from Optical Coherence Tomography Imaging

Yu Kataoka<sup>1</sup>, Jordan Andrews<sup>2</sup>, Rishi Puri<sup>3</sup>, Peter Psaltis<sup>2</sup> and Stephen J. Nicholls<sup>2</sup>

<sup>1</sup>Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, Suita, Japan

<sup>2</sup>Heart Health, South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia

<sup>3</sup>Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada

Due to the pandemics of obesity and diabetes mellitus, especially in the Western countries, atherosclerotic cardiovascular disease (ASCVD) has become a major health burden and is expected to increase in the future. Modifying lipid targets, especially low-density lipoprotein cholesterol (LDL-C) level, has become the first-line therapy for primary and secondary prevention of ASCVD. Intravascular imaging modalities have contributed to elucidating clinical efficacy of lipid lowering therapy on atherosclerotic plaques. Optical coherence tomography (OCT) is a high-resolution imaging tool enables visualization of plaque microstructures associated with its instability. This modality has demonstrated favorable changes in plaque microstructures under lowering LDL-C level. In addition, clinical studies using OCT have suggested potential association of other lipid targets, including triglyceride and high-density lipoprotein cholesterol with plaque microstructures. Given continuing cardiovascular risks despite statin therapy, OCT will be an important imaging modality to evaluate novel therapeutic approaches that potentially modulates plaque instability.

**Key words:** Optical coherence tomography, Low-density lipoprotein cholesterol, Plaque microstructures, Triglyceride, High-density lipoprotein cholesterol

**Abbreviations:** ASCVD = atherosclerotic cardiovascular disease, CAD = coronary artery disease, CETP = Cholesteryl ester transfer protein, HDL-C = high-density lipoprotein cholesterol, IVUS = intravascular ultrasound, LDL-C = low-density lipoprotein cholesterol, LPL = lipoprotein lipase, OCT = optical coherence tomography, VLDL = very-low-density lipoprotein cholesterol

Copyright©2017 Japan Atherosclerosis Society

This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.

## Introduction

Atherosclerotic cardiovascular disease (ASCVD) has become a major health burden due to the pandemic of obesity and diabetes mellitus, especially in Western countries. This suggests the importance of establishing effective therapeutic approaches for the prevention of ASCVD. Accumulating evidence supports atherogenic lipids as important therapeutic tar-

gets associated with the occurrence of ASCVD. In particular, low-density lipoprotein cholesterol (LDL-C) level has been shown as a strong contributor of ASCVD in previous epidemiological and genetic studies<sup>1</sup>. Furthermore, large-scale randomized clinical trials have consistently demonstrated that lowering LDL-C with a statin was associated with a significant reduction of ASCVD<sup>2-7</sup>. This therapeutic regimen also slows progression of coronary atherosclerosis and induces its regression when very low LDL-C level is achieved<sup>8-11</sup>. Based on these observations, the current therapeutic guideline has recommended lowering LDL-C as a first-line therapy for the prevention of ASCVD<sup>12, 13</sup>.

Intravascular imaging has elucidated the clinical

Address for correspondence: Yu Kataoka, Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre, 5-7-1, Fujishirodai, Suita city, Osaka, Japan  
E-mail: yu.kataoka@ncvc.go.jp

Received: December 2, 2016

Accepted for publication: December 26, 2016

efficacy of lipid lowering therapy on atherosclerotic plaques and provides mechanistic insights into the progression and vulnerability of coronary atherosclerosis. Optical coherence tomography (OCT), a novel intravascular imaging modality, has enabled the visualization of plaque microstructures due to its high imaging resolution<sup>14, 15</sup>. Given that plaque microstructures are considered to be associated with its instability<sup>16, 17</sup>, this modality has the great potential to further evaluate the efficacy of lipid lowering therapy on plaque vulnerability. In this review, we summarize accumulating evidences about anti-atherosclerotic efficacy of lipid lowering therapies evaluated by OCT imaging.

### Plaque Microstructures

Plaque microstructure is a compositional feature of atherosclerotic lesions related to its instability. The formation of plaque microstructures occurs through atherosclerotic changes derived by the degree of influx of atherogenic lipids and inflammatory materials<sup>18-22</sup>. The uptake of atherogenic cholesterol-rich lipoproteins from macrophages and the influx of inflammatory materials promote the development of the large lipid core. In addition, it is covered by a fibrous cap, which is developed through accumulation of smooth muscle cells. The fibrous cap is modulated by activated inflammatory reactions, making it thinner. This process leads to the development of thin-cap fibroatheroma. Inflammatory cytokines also promote instability of lesions through neovascularization and macrophage infiltration<sup>18, 21</sup>. The pathophysiology of plaque formation indicates that plaque microstructure is an important contributor to vulnerability of atherosclerotic lesions.

Pathohistological analysis has demonstrated distinct characteristics of plaque microstructures at culprit lesions in patients with sudden cardiac death<sup>16, 17</sup>. In the published world-wide survey, plaque rupture is the main cause of coronary thrombosis (60–70%). Ruptured plaque harbors a large and soft lipid-rich necrotic core covered by a thin fibrous cap. Expansive remodeling, neovascularization, plaque hemorrhage, macrophage infiltration, and spotty calcification have also been more frequently observed. These observations suggest that plaque microstructures are important signatures of vulnerable lesions that cause acute coronary syndrome.

### OCT Imaging

OCT has the capability to visualize plaque microstructures *in vivo*. OCT is an intravascular imaging modality that uses near-infrared light (1300 nm) to create images of atherosclerotic plaques in the coronary artery<sup>14, 15</sup>. The greatest advantage of OCT is its

high resolution of up to 10  $\mu\text{m}$  in an axial resolution and 20  $\mu\text{m}$  in a lateral resolution, which is approximately 10 times higher than that of intravascular ultrasound (IVUS). This produces high quality imaging for plaque microstructures, including fibrous cap, microchannel, and accumulation of lipids and macrophages<sup>14, 15, 23</sup>. A recent study demonstrated that OCT identified thin fibrous cap, plaque rupture site, thrombus, and thin-cap fibroatheroma at culprit lesions in 30 patients with acute myocardial infarction *in vivo*<sup>24</sup>. In another study analyzing 63 patients with coronary artery disease (CAD), culprit plaques harboring vaso vasorum were more likely to associate with thinner fibrous cap, a higher frequency of thin-cap fibroatheroma, and an elevated level of c-reactive protein<sup>25</sup>. Given that other intravascular imaging modalities could not detect plaque microstructures, OCT imaging is an important tool to conduct meticulous evaluation of atherosclerotic lesions and potentially evaluate the efficacy of anti-atherosclerotic therapies.

The disadvantage of OCT imaging is poor tissue penetration. OCT has a penetration depth of 2 to 3 mm, which prohibits imaging beyond the internal elastic lamina. Due to this limited penetration, it is difficult to image atherosclerotic plaques in large arteries. Vessel volume and remodeling pattern cannot be evaluated through this imaging modality. Other limitations of OCT are related predominantly to the features of a light-based energy source, which include poor tissue penetration and interference from blood. It requires continuous infusion of contrast medium during its pullback. As such, OCT is not suitable for quantitative measurement of plaque volume and patients with chronic kidney disease. Despite these limitations, OCT will serve as an important tool for analyzing plaque vulnerability under anti-atherosclerotic medical therapy.

OCT imaging is capable of visualizing other plaque phenotypes associated with acute coronary events. Plaque erosion is characterized by the lesion exhibiting intact fibrous cap and the presence of thrombus, which is observed in 20–30% of subjects with sudden cardiac death<sup>16, 17</sup>. The underlying plaque morphology shows the presence of pathological intimal thickening or a fibroatheroma. Calcified nodules are a rare type of plaque feature related to disruptive nodular calcifications protruding into the lumen<sup>16, 17</sup>. Recent studies have reported frequency of ruptured plaque, erosion, and calcified nodules at culprit lesions in patients with acute myocardial infarction, which is similar to observations in pathohistological analysis<sup>26-28</sup>. The effect of lipid lowering therapy on these atherosclerotic lesions has yet to be determined. Future studies will elucidate natural history of plaque

**Table 1.** Plaque Microstructures under Lowering LDL-C Levels

Statin				
Authors	Subjects	Therapy	Outcomes	Findings
Kataoka, <i>et al.</i> <sup>31)</sup>	280 patients with CAD who received a statin	any type of statin therapy	Fibrous cap thickness	Patients with LDL-C <50 mg/dL were more likely to have fibrous plaque and less likely to have lipid plaques. In addition, LDL-C level was significantly associated with lipid arc and fibrous cap thickness.
Hattori <i>et al.</i> <sup>33)</sup>	42 patients with stable CAD	4 mg pitavastatin vs. standard therapy without any statin	Fibrous cap thickness, percentage lipid volume index	Significant increase in fibrous cap thickness was observed in the pitavastatin group, these changes were not observed in the diet-only group. Differences in the changes in the percentage lipid volume and fibrous cap thickness over time between the pitavastatin and diet groups were highly significant.
Takarada <i>et al.</i> <sup>34)</sup>	40 patients with AMI who received PCI	Statin therapy vs. Standard therapy without a statin	Fibrous cap thickness	Percent change in fibrous cap thickness was greater in statin group (188 ± 64 vs. 117 ± 39%, <i>p</i> < 0.01). when the patients in the statin treatment group were divided into two subgroups (fibrous-cap thickness < median and ≥ median), the thin fibrous-cap group (< median) increased their thickness much more than the thick fibrous-cap group (≥ median).
Statin intensity				
Kataoka, <i>et al.</i> <sup>29)</sup>	275 patients with stable CAD	Standard therapy without a statin vs. low-dose statin vs. high-dose statin	Fibrous cap thickness	Plaques in the high-dose statin group demonstrated a smaller lipid arc and a greater fibrous cap thickness.
Komukai <i>et al.</i> (EASY-FIT) <sup>30)</sup>	70 patients with unstable angina pectoris	5 mg vs. 10 mg atorvastatin	Change in fibrous cap thickness	The increase in fibrous cap thickness was significantly greater with 20 mg/day compared with 5 mg/day of atorvastatin. The increase in fibrous cap thickness correlated with the decrease in serum levels of low-density lipoprotein cholesterol, malondialdehyde-modified low-density lipoprotein, high-sensitivity C-reactive protein, and matrix metalloproteinase-9, and the decrease in grade of OCT-derived macrophages.
Hou <i>et al.</i> <sup>35)</sup>	46 patients with CAD	Atorvastatin 60 mg vs. atorvastatin 20 mg	Change in fibrous cap thickness	Atorvastatin 60 mg induced greater increase in fibrous cap thickness at 6 months. The prevalence of thin-cap fibroatheroma and the presence of macrophage were significantly lower in atorvastatin 60 mg group at 6 months.
Ezetimibe				
Habara <i>et al.</i> <sup>37)</sup>	63 patients with CAD	Combination of fluvastatin + ezetimibe versus fluvastatin alone for 9 months	Change in fibrous cap thickness	Fibrous cap thickness was significantly increased and the angle of the lipid plaque was significantly decreased in both groups. The change in the fibrous cap thickness was significantly greater in the ezetimibe + fluvastatin group.

AMI=acute myocardial infarction, CAD=coronary artery disease, EASY-FIT=Effect of Atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque assessed by optical coherence tomography, LDL-C=low-density lipoprotein cholesterol, PCI=percutaneous coronary intervention


erosion and calcified nodules under lipid modifying therapy by using OCT imaging.

### Lowering LDL-C Levels and Plaque Microstructures

The effect of lowering LDL-C levels on atherosclerotic plaques has been analyzed by a variety of intravascular imaging studies. Recently, OCT imaging

has been used to investigate plaque microstructures under LDL-C lowering therapy with statin or ezetimibe on coronary atheroma *in vivo* (Table 1). It has provided mechanistic insights into plaque stabilization effects under LDL-C lowering therapy.

**1) Statin:** Plaque microstructures at non-culprit lesions under low- and high-dose statin were investi-



**Fig. 1.** Fibrous Cap Thickness, Lipid Arc, and Intensity of Statin


gated in 275 patients with stable CAD who required percutaneous coronary intervention<sup>29)</sup> (**Fig. 1**). Achieved LDL-C levels were  $103.1 \pm 37.9$ ,  $96.3 \pm 40.7$ , and  $80.5 \pm 31.2$  mg/dl in no statin, low-dose, and high-dose statin groups, respectively. Compared to subjects who did not take a statin, thicker fibrous cap ( $p=0.01$ ) and smaller lipid arc ( $p=0.03$ ) were observed in association with dose of statins. In addition, patients receiving a statin were more likely to exhibit a lower frequency of thin-cap fibroatheroma ( $p < 0.001$ ) and vaso vasorum ( $p=0.01$ ). These favorable features were more frequently observed in subjects under high-dose statin who achieved the lowest LDL-C level. The EASY-FIT (Effect of Atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque assessed by optical coherence tomography) trial compared the efficacy of 20 mg and 5 mg atorvastatin on OCT-derived plaque microstructures in 70 patients with unstable angina pectoris<sup>30)</sup> (**Table 1**). On-treatment LDL-C level was significantly lower in 20 mg atorvastatin group [69 mg/dl (interquartile range: 61–80) vs. 78 mg/dl (interquartile range: 66–108),  $p=0.03$ ]. On serial evaluation, 20 mg atorvastatin use was associated with greater increase in fibrous cap thickness [69% (interquartile range: 25–104) vs. 17% (interquartile range: –1–34),  $p < 0.001$ ]. Furthermore, more favorable changes in lipid arc [–27% (interquartile range: from –37 to –20) vs. –8% (interquartile range: –13 to –4),  $p < 0.001$ ] and macrophage grade [–38% (interquartile range: –44 to –31) vs. –24% (interquartile range: –33–0),  $p < 0.001$ ] were also observed in patients receiving 20 mg atorvastatin. Biomarkers associated with fibrous

cap thickness included percent change in LDL-C ( $R=-0.450$ ,  $p < 0.001$ ), malondialdehyde-modified low-density lipoprotein ( $R=-0.283$ ,  $p=0.029$ ), high-sensitivity c-reactive protein ( $R=-0.276$ ,  $p < 0.001$ ), and matrix metalloproteinase-9 ( $R=-0.502$ ,  $p < 0.001$ ) levels<sup>30)</sup>.

The association of achieved LDL-C level with plaque microstructures at non-culprit lesions was investigated in another retrospective analysis<sup>31)</sup>. This study included 280 patients with CAD who received a statin. LDL-C levels  $< 50$  mg/dl and 70 mg/dl were achieved by 13.9% and 29.2% of study subjects, respectively. Fibrous cap thickness was thicker and lipid arc was smaller in association with achieved LDL-C level (**Fig. 2-a** and **-b**). Patients with LDL-C  $< 50$  mg/dl exhibited the thickest fibrous cap, smallest lipid arc, and the lowest frequency of thin-cap fibroatheroma (**Fig. 2a, b, and c**). Even after adjusting for differences in clinical demographics, LDL-C level ( $\beta$  coefficient =  $-0.254$ ,  $p=0.009$ ) and high-dose statin use ( $\beta$  coefficient =  $1.814$ ,  $p=0.003$ ) were independent determinants for fibrous cap thickness. Subgroup analysis elucidated consistent efficacy of achieving very low LDL-C levels in various subsets except diabetic patients (**Table 2**). Favorable effects of achieving very low LDL-C level on fibrous cap thickness were observed in non-diabetic subjects ( $94.6 \pm 52.9$  vs.  $203.5 \pm 93.7$   $\mu\text{m}$ ,  $p < 0.001$ ), whereas there was no significant difference in fibrous cap thickness of diabetic patients with LDL-C  $<$  vs.  $> 50$  mg/dl ( $106.4 \pm 86.9$  vs.  $93.2 \pm 79.6$   $\mu\text{m}$ ,  $p=0.27$ ).


Plaque microstructures in obese patients were analyzed in another OCT imaging study<sup>32)</sup>. This study

**Figure 2-a.**




Adapted from *Atherosclerosis*, 2015; 242: 490-495

**Figure 2-c.**



Adapted from *Atherosclerosis*, 2015; 242: 490-495

**Figure 2-b.**



Adapted from *Atherosclerosis*, 2015; 242: 490-495

**Fig. 2.** Achieving Very Low LDL-C Level and Plaque Microstructures

a. fibrous cap thickness

b. lipid arc


c. TCFA

LDL-C=low-density lipoprotein cholesterol, TCFA = thin-cap fibroatheroma

**Table 2.** Fibrous Cap Thickness under Very Low LDL-C Level in Various Subgroups

	Fibrous cap thickness (um)		p-value	p-value for interaction
	LDL-C < 50 mg/dl	LDL-C ≥ 50 mg/dl		
Age < median (62 years)	203.5 ± 93.7	94.6 ± 52.9	<0.001	0.12
Age ≥ median (62 years)	112.2 ± 79.3	87.9 ± 40.0	0.03	
Male	163.7 ± 94.0	95.9 ± 57.1	<0.001	0.13
Female	128.6 ± 38.1	91.1 ± 35.2	0.03	
BMI < median (29.2 kg/m <sup>2</sup> )	122.3 ± 83.3	95.1 ± 49.1	0.03	0.004
BMI ≥ median (29.2 kg/m <sup>2</sup> )	269.3 ± 66.3	93.7 ± 52.9	<0.001	
Hypertension (-)	120.1 ± 86.3	94.7 ± 56.3	0.03	0.002
Hypertension (+)	202.6 ± 96.5	93.8 ± 48.3	<0.001	
Diabetes (-)	203.5 ± 93.7	94.6 ± 52.9	<0.001	0.003
Diabetes (+)	106.4 ± 86.9	93.2 ± 79.6	0.27	
Non-smoker	183.0 ± 48.3	95.7 ± 57.8	0.003	0.13
Smoker	131.7 ± 98.9	92.7 ± 45.2	0.003	
Atorvastatin use	155.2 ± 110.3	99.1 ± 67.2	0.02	0.51
Rosuvastatin use	233.2 ± 68.2	90.3 ± 51.4	<0.001	

BMI=body mass index, LDL-C=low-density lipoprotein cholesterol



Adapted from Eur J Prev Cardiol, 2015; 22: 1331-1339

**Fig. 3.** Fibrous Cap Thickness under Lowering LDL-C Levels in Obese and Non-obese Patients

LDL-C=low-density lipoprotein cholesterol

investigated 129 obese and 179 non-obese patients with CAD on whom OCT imaging was conducted. In obese patients, thinner fibrous cap ( $85.3 \pm 31.1$  vs.  $110.1 \pm 32.4$   $\mu\text{m}$ ,  $p=0.01$ ) and a higher prevalence of thin-cap fibroatheroma (28.8% vs. 14.3%,  $p=0.01$ ) were observed. These features persisted in multivariate analysis adjusting for clinical demographics. Achieving LDL-C levels  $<70$  mg/dl were associated with thicker fibrous cap in both obese and non-obese patients. However, the fibrous cap thickness in obese patients with LDL-C levels  $<70$  mg/dl were almost similar to that in non-obese subjects with less optimal control of LDL-C (**Fig. 3**). These findings from OCT imaging highlight the benefit of intensive lowering LDL-C with high-intensity statin, whereas diabetic and obese patients are still high-risk categories who require stricter LDL-C control and/or additional therapy targeting other atherogenic targets. Optimizing therapeutic approaches in these subjects will be warranted in future studies.

2) **Ezetimibe:** Ezetimibe is another agent that lowers LDL-C levels by 20% to 30%. It reduces cholesterol absorption through inhibition of the Niemann-Pick C1-like1 protein<sup>33, 36</sup>. The effect of ezetimibe on plaque microstructures was investigated by one recent clinical study that included 63 patients with CAD<sup>37</sup> (**Table 1**). Study subjects were divided into two groups: 1) ezetimibe (10 mg/day)+fluvastatin (30 mg/day) and 2) fluvastatin (30 mg/day) alone. Combination therapy of ezetimibe and fluvastatin was asso-

ciated with a greater reduction of LDL-C levels at nine months after therapy ( $-34.0 \pm 32.0$  mg/dl vs.  $-8.3 \pm 17.4$  mg/dl,  $p<0.001$ ). Serial OCT imaging revealed that change in fibrous cap thickness was significantly greater in the ezetimibe+fluvastatin group ( $0.08 \pm 0.08$  mm vs.  $0.04 \pm 0.06$  mm,  $p<0.001$ ). Change in LDL-C ( $r=-0.60$ ,  $p<0.001$ ), total cholesterol ( $r=-0.57$ ,  $p<0.001$ ) and high-sensitivity c-reactive protein ( $r=0.42$ ,  $p=0.001$ ) levels were significantly correlated to changes in fibrous cap thickness. This result suggests a plaque stabilization effect of ezetimibe, which may account for the lower occurrence of cardiovascular disease in subjects receiving both ezetimibe and statins in a recent clinical trial<sup>38</sup>.

### Residual Lipid Targets and Plaque Microstructures

Substantial amounts of cardiovascular events still occur, even under intensive control of LDL-C level<sup>39, 40</sup>. This residual cardiovascular risk supports the concept that atherosclerosis is a multifactorial process that potentially responds to therapeutic approaches modulating global risks. Considerable attention has been focused on other lipid targets to achieve further reduction of ASCVD. Epidemiological studies have demonstrated the association of high-density lipoprotein cholesterol (HDL-C)<sup>41-49</sup> and triglyceride<sup>50-55</sup> with ASCVD. This evidence indicates that controlling these lipid targets can modulate atherosclerotic plaques and reduce ASCVD under optimal control of LDL-C levels.

### 1) High-density Lipoprotein

HDL particles are an attractive therapeutic target that exhibits a variety of anti-atherosclerotic properties. One major atheroprotective ability of HDL is to promote cholesterol efflux from cells such as macrophages and the related complex physiological process of reverse cholesterol transport<sup>56-58</sup>. HDL also harbors several anti-atherosclerotic properties such as anti-oxidative, anti-inflammatory and anti-thrombotic effects, and vasodilatory abilities<sup>57, 58</sup>. A recent cross-sectional study has elucidated that HDL cholesterol efflux capacity is inversely associated with carotid intima-media thickness ( $\beta$  coefficient per 1-SD increase in efflux capacity;  $-0.03$ , 95% CI; from  $-0.06$  to  $-0.01$ ,  $p=0.003$ ) and the likelihood of angiographic CAD (odds ratio per 1-SD increase,  $0.75$ ; 95% CI,  $0.63-0.90$ ;  $p=0.002$ ) in 2,924 adults without any cardiovascular disease<sup>59</sup>. This observation suggests great potential of HDL modulating therapy to halt atherosclerosis and prevent atherosclerotic cardiovascular events.

The relationship of HDL-C levels with plaque instability at culprit lesions was investigated in 261 subjects with acute coronary syndrome who received percutaneous coronary intervention by using OCT imaging<sup>60</sup>. In this analysis, 47.5% of study subjects exhibited thin-capped fibroatheroma at their culprit sites. They were more likely to have a lower level of HDL-C level ( $39.6 \pm 10.1$  mg/dl vs.  $46.7 \pm 11.7$  mg/dl,  $p < 0.001$ ) and a higher level of LDL-C ( $120.7 \pm 31.1$  mg/dl vs.  $110.0 \pm 28.2$  mg/dl,  $p = 0.004$ ) compared to those without thin-cap fibroatheroma. In addition, HDL-C level was significantly associated with fibrous cap thickness ( $r = 0.27$ ,  $p < 0.001$ ) and lipid arc ( $r = -0.18$ ,  $p = 0.02$ ). Multivariate analysis indicated that HDL-C (odds ratio =  $0.93$ , 95% CI:  $0.90-0.95$ ,  $p < 0.001$ ) and LDL-C (odds ratio =  $1.01$ , 95% CI:  $1.005-1.025$ ,  $p = 0.002$ ) levels were independent predictors for the presence of thin-capped fibroatheroma at culprit lesions<sup>60</sup>. Predictors for thinner fibrous cap thickness included HDL-C ( $\beta$  coefficient =  $0.302$ ,  $p < 0.001$ ), LDL-C ( $\beta$  coefficient =  $-0.172$ ,  $p = 0.008$ ), high-sensitivity c-reactive protein ( $\beta$  coefficient =  $-0.145$ ,  $p = 0.017$ ), and current smoking ( $\beta$  coefficient =  $-0.124$ ,  $p = 0.028$ ) after adjusting the presence of coronary risk factors and the use of statin, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. These observations highlight more high-risk plaque phenotypes in CAD patients with a lower level of HDL-C.

Recent studies have elucidated the association of HDL-C with another novel vulnerable plaque feature, cholesterol crystal, on OCT imaging. Cholesterol crystallization within coronary atheroma has been

shown to promote a local inflammatory response via a Nod-like receptor, NLRP3 inflammasome protein<sup>61, 62</sup>, and induce apoptosis of foam cells, leading to further attraction of macrophages and development of a lipid-rich necrotic core<sup>63, 64</sup>. These inflammatory and apoptotic effects indicate a potential contribution of cholesterol crystal to plaque destabilization. We have already reported more vulnerable features of culprit and non-culprit plaques harboring cholesterol crystals in 250 patients with CAD who undertook percutaneous coronary intervention<sup>65</sup>. At least one cholesterol crystal was found within a target vessel of 36.3% of study population. On OCT imaging analysis, non-culprit lipid plaques containing cholesterol crystals exhibited a smaller fibrous cap thickness ( $84.1 \pm 27.9$   $\mu\text{m}$  vs.  $106.9 \pm 40.1$   $\mu\text{m}$ ,  $p = 0.003$ ), larger lipid index ( $2,357.4 \pm 1,742.7$   $\text{mm}^{\circ}$  vs.  $914.2 \pm 1,151.7$   $\text{mm}^{\circ}$ ,  $p < 0.0001$ ), greater prevalence of thin-cap fibroatheroma (26.9% vs. 5.5%,  $p = 0.005$ ), and microchannel (46.1% vs. 19.4%,  $p < 0.0001$ ). Larger lipid index ( $1,975.1 \pm 765.7$   $\text{mm}^{\circ}$  vs.  $793.8 \pm 1,237.8$   $\text{mm}^{\circ}$ ,  $p = 0.001$ ) and a higher prevalence of thin-cap fibroatheroma (30.3% vs. 2.1%,  $p = 0.01$ ) were also observed at culprit lesions with cholesterol crystals. Another study analyzing 173 patients with CAD also identified more frequent observation of plaque rupture (31.8% vs. 19.3%,  $p = 0.001$ ), thin-cap fibroatheroma (25.8% vs. 7.5%,  $p = 0.002$ ), and macrophage accumulation (75.8% vs. 58.0%,  $p = 0.015$ ) at lesions with cholesterol crystals<sup>66</sup>. Multivariate logistic regression analysis elucidated that HDL-C level  $< 35$  mg/dl was an independent predictor for the presence of cholesterol crystals (odds ratio =  $2.72$ , 95% CI:  $1.27-6.08$ ,  $p = 0.01$ ). These findings suggest HDL as a critical player in plaque stability *in vivo*.

Despite atheroprotective efficacy of HDL, therapeutic agents raising HDL-C levels fail to prove their clinical benefit in the reduction of ASCVD. Cholesteryl ester transfer protein (CETP) inhibitor is an oral agent that elevates HDL-C levels and lowers LDL-C levels via modulation of CETP. The ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events) study was the first study to evaluate the clinical efficacy of torcetrapib, the first CETP inhibitor on cardiovascular outcomes in 15,067 patients at high cardiovascular risk<sup>67</sup>. While torcetrapib increased HDL-C by 72.1% as well as lowered LDL-C level by 24.9%, significant increases in mortality (hazard ratio =  $1.58$ , 95% CI:  $1.14-2.19$ ,  $p = 0.006$ ), and cardiovascular events (hazard ratio =  $1.25$ , 95% CI:  $1.09-1.44$ ,  $p = 0.001$ ) were observed in patients receiving the agent. Additionally, off-target effects, such as elevated blood pressure levels, were observed in the torcetrapib group. The

ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) study compared progression of coronary atherosclerosis on IVUS imaging between torcetrapib and placebo groups<sup>68</sup>. While torcetrapib increased HDL-C level, there was no significant difference in the atheroma progression rate between the two groups (change in percent atheroma volume, +0.19% vs. +0.12%,  $p=0.72$ )<sup>68</sup>. Evacetrapib is a potent CETP inhibitor without off-target effects associated with elevated blood pressure levels<sup>69</sup>. The ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes) study investigated clinical efficacy of evacetrapib in 12,000 patients with atherosclerotic vascular disease who already received a statin. Evacetrapib was associated with a substantial increase in HDL-C levels (104 vs. 46 mg/dl,  $p<0.01$ ) and a lower level of LDL-C (55 vs. 84 mg/dl,  $p<0.01$ ) without major side effects. However, any additive effect on cardiovascular event rates was not observed (12.8% vs. 12.7%, hazard ratio = 1.01, 95% CI: 0.91–1.12,  $p=0.85$ ).

Based on these findings, it could be argued that therapeutic approaches targeting HDL quality rather than its quantity would be beneficial in modifying atherosclerosis. RVX-208 is another novel oral therapeutic agent that generates new HDL particles via enhancing hepatic synthesis of apolipoprotein A-I. This agent has been shown to enhance cholesterol efflux capacities in animal models (ABCA-1 mediated cholesterol efflux capacity:  $15.4\% \pm 1.7\%$  vs.  $7.6\% \pm 1.2\%$ ,  $p<0.001$ )<sup>70</sup>. The clinical efficacy of RVX-208 on atheroma progression was investigated by the ASSURE (ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation) study in 310 patients with acute coronary syndrome<sup>71</sup>. Serial IVUS imaging demonstrated that the use of RVX-208 for 6 months did not modulate changes in percent atheroma volume compared to placebo ( $-0.40\%$  vs.  $-0.30\%$ ,  $p=0.81$ ). However, post-hoc analysis using virtual histology IVUS imaging has elucidated that RVX-208 was associated with a significant increase in fibrous tissue within plaques ( $+1.6\%$  vs.  $-1.3\%$ ,  $p=0.04$ ). This observation suggests the ability of RVX-208 to stabilize atherosclerotic plaques in ACS cases. It remains to be determined whether agents modulating HDL would modify plaque microstructures. Future studies using OCT will further elucidate the anti-atherosclerotic effects of novel therapies modifying HDL quality on plaque microstructures.

## 2) Triglyceride

Triglyceride-rich lipoprotein is an atherogenic particle which exhibits the potential ability to promote atherosclerosis. Following the absorption of dietary lipids, one of triglyceride-rich lipoproteins, chylomicron, is formulated and then hydrolyzed by lipoprotein lipase (LPL)<sup>72, 73</sup>. This process leads to the development of chylomicron remnant. Another triglyceride-rich lipoprotein, very-low-density lipoprotein cholesterol (VLDL) is assembled in the endoplasmic reticulum of hepatocytes. VLDL is hydrolyzed by LPL, generating VLDL remnants, intermediate-density lipoprotein and low-density lipoprotein. Chylomicron and VLDL remnants have been reported to accumulate in vessel wall, leading to foam cell formation. Additionally, these remnants have been shown to increase the expression of pro-inflammatory genes and induce apoptosis<sup>72, 73</sup>. These atherogenic aspects of triglycerides support their contribution to atherosclerosis.

Hypertriglyceridemia, as well as low HDL-C levels, are characteristics of diabetic dyslipidemia. The association of this lipid feature with plaque instability was evaluated by using OCT imaging in diabetic subjects with CAD<sup>74</sup>. This analysis included 128 patients with CAD who already received a statin. On OCT imaging, higher triglyceride/HDL-C ratio contributed to more vulnerable features such as larger lipid arc and cholesterol crystals (**Table 3**). Even after adjusting for differences in clinical demographics, triglyceride/HDL-C ratio was still related to lipidic materials within plaques. This finding highlights the potential benefit in modulating triglycerides and HDL-C in diabetic atherosclerosis.

Suggestive evidence from epidemiological studies has stimulated considerable interests to investigate efficacy of lowering triglyceride levels on cardiovascular outcomes. Fibrates, which are peroxisome proliferator-activated receptor- $\alpha$  agonist, lower triglyceride levels by 20%–50% and raise HDL-C levels by 10%. The ACCORD-LIPID (Action to Control Cardiovascular Risk in Diabetes) study was a large-scale randomized trial which analyzed 5,518 type 2 diabetic subjects with cardiovascular risks<sup>75</sup>. Study subjects were randomized to two groups who received either simvastatin alone or a combination of simvastatin and fenofibrate. Predictably, addition of fenofibrate induced a significant lowering of triglyceride levels (122 mg/dl vs. 144 mg/dl,  $p<0.001$ ) with an increased level of HDL-C (41.2 mg/dl vs. 40.5 mg/dl,  $p=0.01$ ). During 4.7-year observational period, however, there were no significant differences in the occurrence of major cardiovascular events between two groups (2.2% vs. 2.4%, hazard ratio = 0.92, 95% CI:



**Table 3.** Association of TG/HDL-C Ratio with Plaque Microstructures

	TG/HDL-C ratio ≤ 1.39	TG/HDL-C ratio 1.39-4.67	TG/HDL-C ratio > 4.67	P-value
<b>Lipid Content</b>				
Lipid arc (°)	196.3 ± 59.2	158.2 ± 78.2	233.9 ± 95.0	0.01
Longitudinal length of lipid plaque (mm)	4.2 ± 3.7	5.7 ± 5.2	6.0 ± 7.4	0.17
<b>Plaque Microstructures</b>				
Microchannel (%)	20	21	19	0.98
Cholesterol crystal (%)	26.6	21	57.1	0.03
Fibrous cap thickness (µm)	115.3 ± 36.0	137.0 ± 97.1	108.6 ± 54.1	0.42
TCFA (%)	13	15	29	0.23
Calcification (%)	80	63.1	66.6	0.56

HDL-C = high-density lipoprotein cholesterol, TCFA = thin-cap fibroatheroma, TG = triglyceride

0.79 to 1.08,  $p = 0.32$ )<sup>75</sup>). Subgroup analyses identified a favorable trend toward a lower occurrence of major cardiovascular events in diabetic patients with both high triglyceride ( $\geq 204$  mg/dl) and low HDL-C ( $\leq 34$  mg/dl) levels (12.3% vs. 17.3%,  $p = 0.06$ ). Aforementioned OCT findings and this subgroup analysis may support favorable benefits of fibrates in diabetic subjects with high triglyceride and low HDL-C levels.

### Conclusion

Lipid modifying therapy is considered as one of the major therapeutic approaches for primary and secondary prevention of ASCVD. Favorable changes in OCT-derived plaque microstructures under lowering LDL-C support its importance as a therapeutic target to halt atherosclerosis. Several OCT imaging studies suggest plaque stabilization effects through modulation of other lipid targets. Recent innovation in pharmacological regimens has enabled the achievement of very low LDL-C levels beyond statins. A variety of novel agents targeting HDL quality and/or metabolism of triglycerides are under development or investigation in on-going clinical trials. OCT imaging will be expected to play a critical role in the assessment of these novel therapies in the future.

### Acknowledgements

The authors are grateful for the technical expertise of the Atherosclerosis Imaging Core Laboratory of the Cleveland Clinic.

### Financial Support and Sponsorship

None.

### Conflicts of Interest

Yu Kataoka has received research support from Cerenis.

Stephen J Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough and Takeda, consulting fees from AstraZeneca, Pfizer, Merck Schering-Plough, Takeda, Roche, Novo-Nordisk, LipoScience and Anthera and research support from AstraZeneca, Lipid Sciences and Cerenis.

### References

- 1) Ballantyne C, Arroll B, Shepherd J: Lipids and CVD management: towards a global consensus. *Eur Heart J*, 2005; 26: 2224-2231
- 2) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*, 1994; 344: 1383-1389
- 3) Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*, 2004; 35: 1495-1504
- 4) Austin PC, Mamdani MM: Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. *Circulation*, 2005; 112: 1296-1300
- 5) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*, 2004; 364: 685-696

- 6) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. *N Engl J Med*, 1998; 339: 1349-1357
- 7) Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group: PROspective Study of Pravastatin in the Elderly at Risk: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*, 2002; 360: 1623-1630
- 8) Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA*, 2004; 291: 1071-1080
- 9) Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA*, 2006; 295: 1556-1565
- 10) Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE: Effect of two intensive statin regimens on progression of coronary disease. *N Engl J Med*, 2011; 365: 2078-2087
- 11) Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE: Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. *JAMA*, 2016 Nov 15. doi: 10.1001/jama.2016.16951. [Epub ahead of print]
- 12) Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*, 2013; S0735-S0797
- 13) European Association for Cardiovascular Prevention & Rehabilitation<sup>1</sup>, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*, 2011; 32: 1769-1818
- 14) Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Falk E, Feldman MD, Fitzgerald P, Garcia-Garcia HM, Gonzalo N, Granada JF, Guagliumi G, Holm NR, Honda Y, Ikeno F, Kawasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB, Machara A, Manfrini O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake H, Pietrasik A, Prati F, Räber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Suter M, Takarada S, Tanaka A, Terashima M, Thim T, Uemura S, Ughi GJ, van Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R, Waxman S, Weissman NJ, Weisz G; International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT): Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. *J Am Coll Cardiol*, 2012; 59: 1058-1072
- 15) Lowe HC, Narula J, Fujimoto JG, Jang IK: Intracoronary optical diagnostics current status, limitations, and potential. *JACC Cardiovasc Interv*, 2011; 4: 1257-1270
- 16) Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol*, 2000; 20: 1262-1275
- 17) Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R: Update on acute coronary syndromes: the pathologists' view. *Eur Heart J*, 2013; 34: 719-728
- 18) Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J: Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. *Arterioscler Thromb Vasc Biol*, 2005; 25: 2054-2061
- 19) Libby P: Inflammation in atherosclerosis. *Arterioscler Thromb Vasc Biol*, 2012; 32: 2045-2051
- 20) Bennett MR, Sinha S, Owens GK: Vascular Smooth Muscle Cells in Atherosclerosis. *Circ Res*, 2016; 118: 692-702
- 21) Bentzon JF, Otsuka F, Virmani R, Falk E: Mechanisms of plaque formation and rupture. *Circ Res*, 2014; 114: 1852-1866
- 22) Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O: Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. *Circ Res*, 2014; 114: 214-226
- 23) Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlorndorf KH, Kauffman CR, Shishkov M, Kang DH, Halpern EF, Tearney GJ: Characterization of human atherosclerosis by optical coherence tomography. *Circulation*, 2002; 106: 1640-1645
- 24) Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T: Assessment of culprit

- lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angiography. *J Am Coll Cardiol*, 2007; 50: 933-939
- 25) Kitabata H, Tanaka A, Kubo T, Takarada S, Kashiwagi M, Tsujioka H, Ikejima H, Kuroi A, Kataiwa H, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Hirata K, Nakamura N, Mizukoshi M, Imanishi T, Akasaka T: Relation of micro-channel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. *Am J Cardiol*, 2010; 105: 1673-1678
- 26) Jia H, Abtahian F, Aguirre AD, Lee S, Chia S, Lowe H, Kato K, Yonetsu T, Vergallo R, Hu S, Tian J, Lee H, Park SJ, Jang YS, Raffel OC, Mizuno K, Uemura S, Itoh T, Kakuta T, Choi SY, Dauerman HL, Prasad A, Toma C, McNulty I, Zhang S, Yu B, Fuster V, Narula J, Virmani R, Jang IK: In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. *J Am Coll Cardiol*, 2013; 62: 1748-1758
- 27) Higuma T, Soeda T, Abe N, Yamada M, Yokoyama H, Shibutani S, Vergallo R, Minami Y, Ong DS, Lee H, Okumura K, Jang IK: A Combined Optical Coherence Tomography and Intravascular Ultrasound Study on Plaque Rupture, Plaque Erosion, and Calcified Nodule in Patients With ST-Segment Elevation Myocardial Infarction: Incidence, Morphologic Characteristics, and Outcomes After Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*, 2015; 8: 1166-1176
- 28) Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, King P, Nicholls SJ: Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. *Circ Cardiovasc Imaging*, 2016; 9: pii:e004506
- 29) Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. *Am J Cardiol*, 2014; 114: 549-554
- 30) Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, Okumura Y, Shiono Y, Orii M, Shimamura K, Ueno S, Yamano T, Tanimoto T, Ino Y, Yamaguchi T, Kumiko H, Tanaka A, Imanishi T, Akagi H, Akasaka T: Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. *J Am Coll Cardiol*, 2014; 64: 2207-2217
- 31) Kataoka Y, Hammadah M, Puri R, Duggal B, Uno K, Kapadia SR, Murat Tuzcu E, Nissen SE, Nicholls SJ: Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. *Atherosclerosis*, 2015; 242: 490-495
- 32) Kataoka Y, Hammadah M, Puri R, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. *Eur J Prev Cardiol*, 2015; 22: 1331-1339
- 33) Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S, Ishikawa M, Kawai T, Ohta M, Kawai H, Hashimoto T, Takagi Y, Ishii J, Serruys PW, Narula J: Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. *JACC Cardiovasc Imaging*, 2012; 5: 169-177
- 34) Takarada S, Imanishi T, Kubo T, Tanimoto T, Kitabata H, Nakamura N, Tanaka A, Mizukoshi M, Akasaka T: Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. *Atherosclerosis*, 2009; 202: 491-497
- 35) Hou J, Xing L, Jia H, Vergallo R, Soeda T, Minami Y, Hu S, Yang S, Zhang S, Lee H, Yu B, Jang IK: Comparison of Intensive Versus Moderate Lipid-Lowering Therapy on Fibrous Cap and Atheroma Volume of Coronary Lipid-Rich Plaque Using Serial Optical Coherence Tomography and Intravascular Ultrasound Imaging. *Am J Cardiol*, 2016; 117: 800-806
- 36) Katsiki N, Theocharidou E, Karagiannis A, Athyros VG, Mikhailidis DP: Ezetimibe therapy for dyslipidemia: an update. *Curr Pharm Des*, 2013; 19: 3107-3114
- 37) Habara M, Nasu K, Terashima M, Ko E, Yokota D, Ito T, Kurita T, Teramoto T, Kimura M, Kinoshita Y, Tsuchikane E, Asakura Y, Matsubara T, Suzuki T: Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. *Am J Cardiol*, 2014; 113: 580-587
- 38) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med*, 2015; 372: 2387-2397
- 39) Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA*, 2005; 294: 2437-2445
- 40) LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*, 2005; 352: 1425-1435
- 41) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med*, 1977; 62: 707-714
- 42) Rhoads GG, Gulbrandsen CL, Kagan A: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. *N Engl J Med*, 1976; 294: 293-298
- 43) Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA: High-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and

- women: the follow-up study of the Lipid Research Clinics Prevalence Study. *Am J Epidemiol*, 1990; 131: 32-47
- 44) Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A: High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. *Eur Heart J*, 2005; 26: 890-896
  - 45) Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E: Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. *Arterioscler Thromb Vasc Biol*, 2009; 29: 424-430
  - 46) Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ; JUPITER Trial Study: HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. *Lancet*, 2010; 376: 333-339
  - 47) Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorf A, Beere PA, Watson DJ, Downs JR, de Cani JS: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). *Circulation*, 2000; 101: 477-484
  - 48) Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E: Relationship between plasma LDL concentration during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. *Circulation*, 1998; 97: 1446-1452
  - 49) Boekholdt SM, Arsenaault BJ, Hovingh GK, Mora S, Pedersen TR, LaRosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ: Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. *Circulation*, 2013; 128: 1504-1512
  - 50) Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*, 2007; 298: 299-308
  - 51) Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA*, 2007; 298: 309-316
  - 52) Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. *JAMA*, 2008; 300: 2142-2152
  - 53) Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J: Major lipids, apolipoproteins, and risk of vascular disease. *JAMA*, 2009; 302: 1993-2000
  - 54) Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol*, 2008; 51: 724-730
  - 55) Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, LaRosa JC, Larsen ML, Lindahl C, Olsson AG, Tikkanen MJ, Waters DD, Pedersen TR; Steering Committees of IDEAL and TNT Trials: Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. *Am J Cardiol*, 2009; 104: 459-463
  - 56) Rader DJ, Hovingh GK: HDL and cardiovascular disease. *Lancet*, 2014; 384: 618-625
  - 57) Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD: High-density lipoprotein function, dysfunction, and reverse cholesterol transport. *Arterioscler Thromb Vasc Biol*, 2012; 32: 2813-2820
  - 58) Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation*, 1989; 79: 8-15
  - 59) Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW: HDL cholesterol efflux capacity and incident cardiovascular events. *N Engl J Med*, 2014; 371: 2383-2393
  - 60) Ozaki Y, Tanaka A, Komukai K, Ishibashi K, Tanimoto T, Kitabata H, Ino Y, Kubo T, Imanishi T, Akasaka T: High-density lipoprotein cholesterol level is associated with fibrous cap thickness in acute coronary syndrome. *Circ J*, 2013; 77: 2982-2989
  - 61) Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature*, 2010; 464: 1357-1361
  - 62) Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, Eklund KK: Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. *PLoS One*, 2010; 5: e11765
  - 63) Kellner-Weibel G, Jerome WG, Small DM, Warner GJ, Stoltenberg JK, Kearney MA, Corjay MH, Phillips MC, Rothblat GH: Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. *Arterioscler Thromb Vasc Biol*, 1998; 18: 423-431
  - 64) Geng YJ, Phillips JE, Mason RP, Casscells SW: Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture. *Biochem Pharmacol*, 2003; 66: 1485-1492
  - 65) Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Cholesterol crystals associate with coronary plaque vulnerability in vivo. *J Am Coll Cardiol*, 2015; 65: 630-632
  - 66) Nishimura S, Ehara S, Hasegawa T, Matsumoto K, Yoshikawa J, Shimada K: Cholesterol crystal as a new feature of coronary vulnerable plaques: An optical coherence tomog-

- raphy study. *J Cardiol*, 2016 May 4. pii: S0914-5087(16)30049-1
- 67) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*, 2007; 357: 2109-2122
- 68) Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. *N Engl J Med*, 2007; 356: 1304-1316
- 69) Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlan E, Nissen SE: Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. *JAMA*, 2011; 306: 2099-2109
- 70) Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J: RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. *J Am Coll Cardiol*, 2010; 55: 2580-2589.
- 71) Nicholls SJ, Puri R, Wolski K, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Hu B, Uno K, Kataoka Y, Herrman JP, Merkely B, Borgman M, Nissen SE: Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. *Am J Cardiovasc Drugs*, 2016; 16: 55-65.
- 72) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism.; Council on Arteriosclerosis, Thrombosis and Vascular Biology.; Council on Cardiovascular Nursing.; Council on the Kidney in Cardiovascular Disease: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*, 2011; 123: 2292-2333
- 73) Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoğlu L, Tybjaerg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J*, 2011; 32: 1345-1361
- 74) Kataoka Y, Andrews J, Uno K, Puri R, Hammadah M, Duggal B, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Triglyceride/high-density lipoprotein cholesterol ratio associates with plaque instability in diabetic patients receiving a statin: frequency domain optical coherence tomography analysis. *Eur Heart J*, 2016; 37 suppl1: 735
- 75) ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*, 2010; 362: 1563-1574